Related Experiment Video
Updated: Aug 2, 2026
09:27
New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
Published on: May 30, 2013
Is vitamin E supplementation a useful agent in AIDS therapy?
1Nutritional Sciences Program, University of Arizona, Tucson 85724.
Progress in Food & Nutrition Science
|October 1, 1993
Summary
Vitamin E supplementation may offer a low-toxicity nutritional therapy for Acquired Immune Deficiency Syndrome (AIDS). This review explores its potential to combat immune dysfunction and nutritional deficits in HIV-positive individuals.
Area of Science:
- Immunology
- Nutrition Science
- Retroviral Infections
Background:
- Acquired Immune Deficiency Syndrome (AIDS) is the advanced stage of human immunodeficiency virus (HIV) infection, characterized by severe immunosuppression.
- Current pharmacological treatments like zidovudine (AZT) have limitations, including toxicity, limited efficacy in improving immune function, and the emergence of drug-resistant strains.
- Nutritional deficiencies and immune dysfunctions are key pathological features of AIDS, creating a need for alternative therapeutic strategies.
Purpose of the Study:
- To review the therapeutic potential of vitamin E supplementation in managing Acquired Immune Deficiency Syndrome (AIDS).
- To explore the immunoenhancing and antioxidant properties of vitamin E in the context of HIV infection.
- To evaluate evidence from animal and human studies supporting vitamin E's role in mitigating AIDS-related pathologies.
Main Methods:
- Literature review of existing studies on vitamin E supplementation in animal models and human subjects with HIV/AIDS.
- Analysis of immunological, nutritional, and pathological changes associated with AIDS.
- Examination of the properties of vitamin E, including its immunoenhancing and antioxidant effects.
Main Results:
- Vitamin E exhibits immunoenhancing and antioxidant properties that may counteract AIDS-related abnormalities.
- Abnormalities observed in AIDS patients show similarities to conditions that can be improved by vitamin E intake.
- Evidence suggests vitamin E may help normalize immune dysfunctions and nutritional status, potentially slowing disease progression.
Conclusions:
- Vitamin E supplementation presents a promising, low-toxicity nutritional therapy for individuals with HIV/AIDS.
- Its immunoenhancing and antioxidant effects could help manage disease progression and associated symptoms.
- Further clinical trials are warranted to establish vitamin E's efficacy as an adjunct therapy in human AIDS treatment.
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:29Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...